Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    AUT022063
Previous Study | Return to List | Next Study

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss (CLARITY-1)

This study has been completed.
Information provided by (Responsible Party):
Autifony Therapeutics Limited Identifier:
First received: January 19, 2015
Last updated: September 14, 2016
Last verified: September 2016
This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.

Condition Intervention Phase
Age-Related Hearing Loss
Drug: AUT00063
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study]

Resource links provided by NLM:

Further study details as provided by Autifony Therapeutics Limited:

Primary Outcome Measures:
  • Change in hearing loss after 4 weeks of treatment [ Time Frame: 28 days ]
    To compare the change from baseline (Day 1 to Day 28) between AUT00063 and placebo, on a speech-in-noise deficit

Secondary Outcome Measures:
  • Change in parameters of hearing performance from baseline to day 28 [ Time Frame: 28 days ]
    Changes in hearing tests

  • To further investigate the safety and tolerability profile of repeat administration of AUT00063 by assessing vital signs, physical examination, laboratory exams and ECG [ Time Frame: 42 days ]
    To investigate the safety and tolerability of AUT00063 by assessing vital signs, physical examination, laboratory exams and ECG

  • Pharmacokinetic of AUT00063, plasma levels [ Time Frame: 28 days ]
    Exposure of AUT00063 ng/ml, in plasma levels at Day 28

Enrollment: 78
Study Start Date: January 2015
Study Completion Date: June 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AUT00063 (600 mg capsules)
3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
Drug: AUT00063
600 mg, orally, once a day, for 4 weeks
Other Name: Experimental
Placebo Comparator: (AUT00063 placebo capsules)
3 capsules of placebo, to take orally once daily with food for 4 weeks
Drug: Placebo
orally, once a day, for 4 weeks
Other Name: Comparator

Detailed Description:

Reduced activity at certain sites in the brain (called "voltage-gated potassium channels") has been linked to hearing problems, like age-related loss of hearing or tinnitus (a 'ringing' or buzzing noise in the ears).

AUT00063 is an experimental new medicine that enhances the action of these specific channels and so may treat the brain component of these hearing problems.

The main purpose of this study is to try to demonstrate an improvement in a speech-in-noise deficit after 4 weeks of treatment with the study drug versus the placebo (dummy drug which does not contain the drug). Subjects will undergo a safety follow-up after the treatment period.

Safety and efficacy will be determined by looking at a number of assessments (physical examinations, blood sampling, hearing assessments, questionnaires, etc.).

The amount of drug in the blood will also be measured. It is expected that around 70 people (at least 35 in each arm) with age-related hearing loss may take part in the study. The study participants will be recruited at around 13 sites in the USA.


Ages Eligible for Study:   50 Years to 89 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Be between ages 50-89 years old
  • American-English speaking
  • Have difficulty hearing speech in a noisy environment
  • No recent history of middle ear disease
  • No severe insomnia, major depressive disorders, severe anxiety or post-traumatic stress disorder
  • Not a current or previous user of hearing aids. You are eligible if you were noncompliant and stopped wearing a hearing aid device >6 months earlier for intermittent use or >3 years if you were a full-time consistent user of hearing aid devices
  • Not be dependent on alcohol or drugs
  • Have not participated in another research study within 30-days
  • If female, you must confirm to be non child bearing (post-menopausal for at least 12-months or surgically sterile)
  • If male, you must confirm to use a barrier method (condom)
  • Not be a professional musician
  • No history of important cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major disease deemed clinically significant by the study doctor

While you are in the study, you must:

  • Follow the instructions you are given
  • Come to the study centre for all visits with the study doctor or study staff
  • Answer the telephone at the scheduled date and time for the 2 telephone calls
  • Tell the study doctor or study staff about any changes in your health or the way you feel
  • Tell the study doctor or study staff if you want to stop being in the study at any time
  • Bring your Diary to each visit
  • Not eat or drink anything containing Grapefruit beginning 7-days before Baseline visit (Visit 3, Day 1) until the end of the study
  • Use sun screen if you plan to sunbathe
  • Not use headphones or headsets at high volume
  • Not use hearing aids or devices at any time during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02345031

United States, California
Sacramento ENT
Sacramento, California, United States, 95815
United States, Colorado
Colorado ENT and Allergy
Colorado Springs, Colorado, United States, 80909
United States, Florida
ENT Associates of South Florida
Boca Raton, Florida, United States, 33487
QPS MRA (Miami Research Associates)
Miami, Florida, United States, 33143
University of South Florida
Tampa, Florida, United States, 33620
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55095
United States, Mississippi
The University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, New York
Long Island Jewish Medical Center
New Hyde Park, New York, United States, 11042
United States, North Carolina
PMG Research Inc.
Wilmington, North Carolina, United States, 28401
Piedmont Ear, Nose, & Throat Associates
Winston-Salem, North Carolina, United States, 27103
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Utah
Jean Brown Research
Murray, Utah, United States, 84107
Sponsors and Collaborators
Autifony Therapeutics Limited
Principal Investigator: Robert Frisina, PhD Director Global Center for Hearing and Speech Research
  More Information

Responsible Party: Autifony Therapeutics Limited Identifier: NCT02345031     History of Changes
Other Study ID Numbers: AUT022063
Study First Received: January 19, 2015
Last Updated: September 14, 2016

Keywords provided by Autifony Therapeutics Limited:
hearing loss

Additional relevant MeSH terms:
Hearing Loss
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Hearing Loss, Sensorineural processed this record on April 28, 2017